Hepatology

Article	Citations
	1495
Reply: Fiber and whole grain intakes in relation to liver cancer risk—An analysis in 2 prospective cohorts and systematic review and meta-analysis of prospective studies	1305
Validation and expansion of Baveno VII criteria for cACLD and CSPH based on liver stiffness and platelet count: Correlation with risk of hepatic decompensation and death	1199
Retracted	741
Effectiveness and safety of glecaprevir/pibrentasvir for 8 weeks in the treatment of patients with acute hepatitis C: A single-arm retrospective study	496
Letter to the editor: The precise relationship between MELD and survival without a liver transplant	425
Cover Image	334
Letter to the editor: The role of aquaporin 9 in modeling of ornithine transcarbamylase deficiency	326
Late-Breaking Abstracts	281
Boosting Success: Optimizing Thiopurine Therapy in Autoimmune Hepatitis With Allopurinol	253
Post-vax vein vigilance: Unmasking splanchnic thrombosis risks	218
Acute encephalopathy without hyperammonemia has a different presentation than overt HE and displays a similarly severe prognosis	196
Higher level of Hepatitis B Surface antigen associated with delayed development of hepatocellular carcinoma in immune-tolerant patients	192
Hepatic encephalopathy—We are no longer those who believe that reality is what we perceive	191
Moving beyond the liver – proteomics as a molecular footprint of systemic damage in metabolic dysfunction-associated steatotic liver disease	182
Letter to the Editor: Regarding terlipressin-related patient outcomes in hepatorenal syndrome-acute kidney injury	171
Requirement of RORα for maintenance and antitumor immunity of liver‐resident natural killer cells/ILC1s	170
Hepatocyte‐specific deletion of adipose triglyceride lipase (adipose triglyceride lipase/patatin‐like phospholipase domain containing 2) ameliorates dietary induced steatohepatitis in mice	169
Changing epidemiology of hepatocellular cancer in the United States: Winning the battle but it is not over yet	162
Letter to the editor: Beneath the surface of the pandemic: Persons with alcohol‐associated liver disease need our attention	155
Letter to the editor: Treatment options for 3–5‐cm solitary HCC—Need a closer look!	155
REPLY:	153
Alan Hofmann (1931‐2021): A career well spent understanding bile acids	151
Dysregulation of RalA signaling through dual regulatory mechanisms exerts its oncogenic functions in hepatocellular carcinoma	148
Reply	147

Letter to the Editor: LO2, a misidentified cell line: Some data should be interpreted with caution	144
PGD2/DP1 axis promotes liver regeneration by secreting Wnt2 in KCs in mice	143
Reply: Can pFIB scores reliably exclude significant liver fibrosis in pediatric MASLD?	141
Letter to the editor: Targeted decrease of portal hepatic pressure gradient immediately after TIPS improves ascites control and prognosis	133
More immunosuppressive, more immunotherapy responsive? A double-edged sword of HBV-induced immune response in HCC	133
Letter to the Editor: Insurance should cover vancomycin for primary sclerosing cholangitis	129
Letter to the Editor: The Hepa 1–6 may not be suitable for use in hepatocellular carcinoma models to explore responses to drug therapy	122
Reply: Medications promoting abstinence in alcohol-associated cirrhosis	122
Precipitous changes in nomenclature and definitions—NAFLD becomes SLD: Implications for and expectations of AASLD journals	121
Group‐2 Innate Lymphoid Cells Promote HCC Progression Through CXCL2‐Neutrophil‐Induced Immunosuppression	117
Obituary for Roberto J. Groszmann—The Father of Portal Hypertension	117
Analysis and Validation of Human Targets and Treatments Using a Hepatocellular Carcinoma–Immune Humanized Mouse Model	116
Gastrodin Improves Nonalcoholic Fatty Liver Disease Through Activation of the Adenosine Monophosphate–Activated Protein Kinase Signaling Pathway	115
ZNT1 and Zn2+ control TLR4 and PD-L1 endocytosis in macrophages to improve chemotherapy efficacy against liver tumor	115
Multiomics approaches for identifying the PANoptosis signature and prognostic model via a multimachine-learning computational framework for intrahepatic cholangiocarcinoma	115
Stellate cell-specific adhesion molecule protocadherin 7 regulates sinusoidal contraction	115
Efficacy and safety of infliximab in patients with autoimmune hepatitis	114
Access to technology to support telehealth in areas without specialty care for liver disease	109
Switch‐associated protein 70 protects against nonalcoholic fatty liver disease through suppression of TAK1	108
Regulatory role and translational potential of CCL11 in liver fibrosis	105
Implementation of a controlled human infection model for evaluation of HCV vaccine candidates	104
Reply: Liver stiffness progression comparison between diabetics and non-diabetics with biopsy-proven metabolic dysfunction-associated steatosis	104
Plasma proteomic signature of fatty liver disease: The Rotterdam Study	102
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease	102
NOD‐like receptor protein 3 activation causes spontaneous inflammation and fibrosis that mimics human NASH	102
Comparison of pharmacological therapies in metabolic dysfunction–associated steatohepatitis for fibrosis regression and MASH resolution: Systematic review and network meta-analysis	101
	99
Letter to the Editor: Comparative efficacy of pharmacologic therapies for MASH in reducing liver fat content—Systematic review and network meta-analysis	98
	97
Letter to the Editor: Learning more about the safety of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma	97
Letter to the Editor: Hepatic decompensation is the major driver of mortality in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatm	95
Instructions to Authors	95
Letter to the Editor: Primary sclerosing cholangitis and autoimmune hepatitis—Distinct or common autoimmune penetrance?	95
Letter to the editor	94
Understanding advanced cystic fibrosis liver disease through genetic variation: Where do the pathways lead and how much further must we go?	94
Healthy peribiliary glands are necessary for successful liver transplantation	93
Erratum	92
Dedifferentiation‐associated inflammatory factors of long‐term expanded human hepatocytes exacerbate their elimination by macrophages during liver engraftment	90
Endpoints and New Options for Treatment of Chronic Hepatitis D	87
Letter to the Editor: Enhancing the rigor and impact of cholangiocarcinoma research: Addressing key concerns in the PTPN9-FGFR2 interaction study	85
Deciphering the spatial tumor microenvironment in intrahepatic cholangiocarcinoma	85
The relationship between mean arterial pressure and terlipressin in hepatorenal syndrome-acute kidney injury reversal: A post hoc analysis	84
Erratum: AASLD Practice Guidance on Acute-on-chronic liver failure and the management of critically ill patients with cirrhosis	83
Tumor-derived CCL2 drives tumor growth and immunosuppression in IDH1-mutant cholangiocarcinoma	83
Letter to the editor: Is PAI‐1 a thrombotic biomarker in NASH cirrhosis?	82
Letter to the editor: Regression of liver fibrosis after bariatric operations: A glass two‐third full rather than half empty	80
Letter to the Editor: Overlooking the important factor: Hypoxia	79
Reply	79
In vivo imaging of calcium dynamics in zebrafish hepatocytes	78
Magnetic resonance elastography for prediction of long‐term progression and outcome in chronic liver disease: A retrospective study	78

Extracellular Signal‐Regulated Kinase 5 Regulates the Malignant Phenotype of Cholangiocarcinoma Cells	76
MRI‐Based Iron Phenotyping and Patient Selection for Next‐Generation Sequencing of Non–Homeostatic Iron Regulator Hemochromatosis Genes	76
REPLY:	76
Interleukin 8-CXCR2–mediated neutrophil extracellular trap formation in biliary atresia associated with neutrophil extracellular trap–induced stellate cell activation	75
Divergent trends in cirrhosis and liver cancer highlight the ongoing efforts required for hepatitis elimination	75
Synergistic combination of cytotoxic chemotherapy and cyclin‐dependent kinase 4/6 inhibitors in biliary tract cancers	75
Stard1 promotes cholestatic liver injury and disease progression by sensitizing to bile acid hepatotoxicity	75
Erratum: Identification and characterization of a hepatic IL-13–producing ILC3-like population potentially involved in liver fibrosis	74
Letter to the Editor	74
Much more needed in natural history of Alagille syndrome	73
With Alcohol as the Fuel, COVID Is the Match	73
Reply: Several issues to consider in the study of hepatocellular carcinoma progression mechanism	72
The spectrum of primary liver cancers: heterogeneity and continuity. A foundation for diagnosis and treatment of cancer	72
Hepatology Highlights	72
Introducing Raymond T. Chung, M.D., Our 2021 AASLD President	72
To Be or Not to Be	71
CD44 in myEloid cells is a major driver of liver inflammation and injury in alcohol-related liver disease	71
Use of noninvasive scores to predict hepatic steatosis: Flaws and caveats	70
The international quest for the imaging diagnosis of liver cancer	69
Immunobiology of primary sclerosing cholangitis	67
Reply: How does bile acid–induced IRF3 phosphorylation mediate cholestatic liver and kidney injury?—More needs to be known	67
Solving the puzzle of fibrosis resolution in alcohol-associated liver disease: An insight from KDM5 demethylases and LXR activation	67
Therapeutic manipulation of the microbiome in liver disease	67
Letter to the Editor: Restructuring the Gut Microbiota of Patients with Cirrhosis After HCV Eradication: A Matter of Time?	66
Two Faces of Neutrophils in Liver Disease Development and Progression	66
Hepatocellular carcinomas, exhibiting intratumor fibrosis, express cancer-specific extracellular matrix remodeling and WNT/TGFB signatures, associated with poor outcome	66
Clinical decision support and electronic interventions to improve care quality in chronic liver diseases and cirrhosis	66
The digital determinants of liver disease	66
Computational drug prediction in hepatoblastoma by integrating pan-cancer transcriptomics with pharmacological response	66
Emergence of highly profibrotic and proinflammatory Lrat + Fbln2 + HSC subpopulation in alcoholic hepatitis	65
Fontan‐associated liver disease	65
Epigenome‐Wide Analysis of Methylation Changes in the Sequence of Gallstone Disease, Dysplasia, and Gallbladder Cancer	64
NAFLD‐related hepatocellular carcinoma: The growing challenge	64
Responsible Inclusion of Pregnant Individuals in Eradicating HCV	64
Erratum: Effects of trientine and penicillamine on intestinal copper uptake: A mechanistic 64Cu PET/CT study in healthy humans	64
Outcomes of pregnancy in autoimmune hepatitis: A population‐based study	63
Circulating TREM2 as a noninvasive diagnostic biomarker for NASH in patients with elevated liver stiffness	63
NASHFit: A randomized controlled trial of an exercise training program to reduce clotting risk in patients with NASH	63
Loss‐of‐Function Genetic Screening Identifies Aldolase A as an Essential Driver for Liver Cancer Cell Growth Under Hypoxia	62
5S rRNA pseudogene transcripts are associated with interferon production and inflammatory responses in alcohol-associated hepatitis	62
Bariatric surgery for metabolic dysfunction-associated steatotic liver disease (MASLD): Current knowledge of mechanisms	62
Effect of tenofovir-based HIV pre-exposure prophylaxis against HBV infection in men who have sex with men	62
Metabolic dysfunction-associated steatotic liver disease and the heart	62
National prevalence estimates for steatotic liver disease and subclassifications using consensus nomenclature	61
A strategy of vascular‐targeted therapy for liver fibrosis	61
The clot and the complicated consult	61
A Simple Bacterium Links Heart Infection to Inflammatory Liver Disease	61
Reply: Regarding the use of decision curve analysis in predicting long-term complications of liver cirrhosis	61
Platelet-derived mitochondria regulate lipid metabolism in nonalcoholic steatohepatitis through extracellular vesicles	60
Enoxacin Up‐Regulates MicroRNA Biogenesis and Down‐Regulates Cytotoxic CD8 T‐Cell Function in Autoimmune Cholangitis	60
Efficiently Restored Thrombopoietin Production by Ashwell‐Morell Receptor and IL‐6R Induced Janus Kinase 2/Signal Transducer and Activator of Transcription Signaling Early After Partial Hepatectomy	60
Clonal hematopoiesis of indeterminate potential and risk of hepatocellular carcinoma: New kids on the block	60
Letter to the editor: Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child‐Pugh A and B cirrhosis: A real‐world study—Sh	59
Malignant progression of liver cancer progenitors requires lysine acetyltransferase 7–acetylated and cytoplasm‐translocated G protein GαS	59
Reply	59
Early detection of primary liver cancer using plasma cell‐free DNA fragmentomics: Do all the pieces come together?	59
Letter to the editor: RECAM for the diagnosis of DILI—Is it time to incorporate additional pharmacological criteria?	59
Reply	58
PNPLA3 rs738409 and risk of fibrosis in NAFLD: Exploring mediation pathways through intermediate histological features	58
REPLY:	58
Hepatology Highlights	58
Unraveling bidirectional evolution of unstable mitochondrial DNA mutations in hepatocellular carcinoma at single-cell resolution	57
Erratum: Inhibition of microRNA-24 expression in liver prevents hepatic lipid accumulation and hyperlipidemia	57
The role of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in managing metabolic dysfunction–associated steatotic liver disease	57
Downstaging of hepatocellular carcinoma before liver transplantation: Results from a national multicenter prospective cohort study	57
Letter to the Editor: Recognizing Significant Role of Neoadjuvant Radiotherapy for HCC With Vascular Invasion	56
Manuscript best practices: Takeaways from a community conversation	56
In Utero Exposure to Mercury Is Associated With Increased Susceptibility to Liver Injury and Inflammation in Childhood	56
An Unexpected Line of Defense: Hepatoprotective Eosinophils in Ischemia‐Reperfusion Injury	56
The Addition of C‐Reactive Protein and von Willebrand Factor to Model for End‐Stage Liver Disease‐Sodium Improves Prediction of Waitlist Mortality	56
Oral Abstracts	56
Letter to the Editor: Exchangeable copper in the Danish cohort of patients with Wilson disease	55
Cell therapies and liver organogenesis technologies: Promising strategies for end-stage liver disease	55
The “shell game” after objective response in patients with advanced HCC treated with immunotherapy	55
Letter to the Editor: Acute rejection after liver transplantation with machine perfusion versus static cold storage: A systematic review and meta-analysis	54
Determining safe washout period for immune checkpoint inhibitors prior to liver transplantation: An international retrospective cohort study	54
HEAR-MHE study: Automated speech analysis identifies minimal hepatic encephalopathy and may predict future overt hepatic encephalopathy	54
Distinct structural and dynamic components of portal hypertension in different animal models and human liver disease etiologies	54
Letter to the Editor: NAFLD, MAFLD or MASLD? Cut the Gordian knot with “Ludwig disease”	53
Letter to the Editor: Cautious interpretation of the association between finite treatment and better prognosis in initially HBeAg-negative hepatitis B patients with cirrhosis	53

Reply	53
Letter to the Editor: Statins as potential confounding factors to investigate the association between the use of GLP-1 receptor agonists and risk of HCC	52
Hepatic GDP-fucose transporter SLC35C1 attenuates cholestatic liver injury and inflammation by inducing CEACAM1 N153 fucosylation	52
The outcome of boosting mitochondrial activity in alcohol-associated liver disease is organ-dependent	51
Letter to the Editor: Can pFIB scores reliably exclude significant liver fibrosis in pediatric MASLD?	51
Reply	51
Acute rejection after liver transplantation with machine perfusion versus static cold storage: A systematic review and meta-analysis	51
Racial and ethnic disparities in early treatment with immunotherapy for advanced HCC in the United States	50
Pathway to global elimination of hepatitis B: HBV cure is just the first step	50
SERPINA12 promotes the tumorigenic capacity of HCC stem cells through hyperactivation of AKT/β-catenin signaling	50
Reply	50
A Transcriptomic Signature for Risk‐Stratification and Recurrence Prediction in Intrahepatic Cholangiocarcinoma	50
Letter to the Editor: Association between birth weight, preterm birth, and nonalcoholic fatty liver disease in a community-based cohort	50
Cancer Risk in Patients With Biopsy‐Confirmed Nonalcoholic Fatty Liver Disease: A Population‐Based Cohort Study	49
Optimizing thiopurine therapy in autoimmune hepatitis: A multicenter study on monitoring metabolite profiles and co-therapy with allopurinol	49
Gene Deconvolution Reveals Aberrant Liver Regeneration and Immune Cell Infiltration in Alcohol‐Associated Hepatitis	49
Future directions in acute liver failure	49
Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child‐Pugh A and B cirrhosis: A real‐world study	49
E. coli and the etiology of human PBC: Antimitochondrial antibodies and spreading determinants	49
CAFs shape myeloid‐derived suppressor cells to promote stemness of intrahepatic cholangiocarcinoma through 5‐lipoxygenase	49
Letter to the editor: Considerations on the use of the liver transplant comorbidity index (LTCI)	49
Bile metabolic fingerprints distinguish biliary tract cancer from benign biliary diseases	49
More than a lark? LRRK2 inhibitors to treat alpha-1 antitrypsin deficiency	48
Reply: Can plasma FSTL-1 levels serve as a reliable biomarker for advanced fibrosis?	48
Reply: Quality indicators and the safety profile of endoscopic intervention in patients with bleeding esophageal varices	48
Table of contents	48
Genetic Determinants of Outcome in Intrahepatic Cholangiocarcinoma	48
Reduction of Z alpha-1 antitrypsin polymers in human iPSC-hepatocytes and mice by LRRK2 inhibitors	48
Masthead	48
HNF4α-CDKL3 axis restricts MASLD progression by targeting FoxO1 via non-canonical phosphorylation	48
Letter to the Editor: NAFLD/MAFLD: One size does not fit all, certainly not for children!	47
Table of contents	47
Cover Image	47
Letter to the editor: Relevance of population‐based cutoffs to define frailty in clinical studies	46
Letter to the editor: High rate of clinical and immunological response in patients with HCV‐associated cryoglobulinemia	46
Masthead	46
Reply	46
Histone Deacetylase Sirtuin 1 Promotes Loss of Primary Cilia in Cholangiocarcinoma	45
Letter to the editor: Is NAFLD a bystander or contributor to coronary artery disease?	45
Masthead	45
Cover Image	45
Pseudouridine synthase 1 promotes hepatocellular carcinoma through mRNA pseudouridylation to enhance the translation of oncogenic mRNAs	45
Erratum for Ren, H et al. Sirtuin 2 prevents liver steatosis and metabolic disorders by deacetylation of hepatocyte nuclear factor 4α	45
Reply	44
Early screening, diagnosis and recurrence monitoring of hepatocellular carcinoma in patients with chronic hepatitis B based on serum N-glycomics analysis: A cohort study	44
Clinicogenomic characteristics and synthetic lethal implications of germline homologous recombination‐deficient hepatocellular carcinoma	44
Neutrophil extracellular traps promote MASH fibrosis by metabolic reprogramming of HSC	44
Letter to the editor: HuR in liver homeostasis	44
Tripartite motif‐containing protein 31 confers protection against nonalcoholic steatohepatitis by deactivating mitogen‐activated protein kinase kinase kinase 7	43
Dissecting Early Relapse in Liver Cancer, One Cell at a Time	42
Imaging for better responses to immunotherapy in hepatocellular carcinoma	42
Neoadjuvant and adjuvant therapy for biliary tract cancer: Advances and limitations	42
Letter to the Editor: Liver Stiffness by Transient Elastography to Detect Porto‐sinusoidal Vascular Liver Disease	42
Letter to the Editor: Is right heart assessment vital for evaluating terlipressin-related outcomes in hepatorenal syndrome-acute kidney injury?	42
Fine-tuning of hepatitis C virus immune evasion through hypervariable region 1 insertions	42
Presenting the new incoming editorial team for hepatology: Team members and perspectives	42
Gut microbiome features associated with liver fibrosis in Hispanics, a population at high risk for fatty liver disease	42
Letter to the Editor: Influence of liver stiffness heterogeneity on staging fibrosis in patients with nonalcoholic fatty liver disease	42
Reply: Development and validation of pFIB scores for exclusion of significant liver fibrosis in pediatric MASLD	41
Reply: The associations between hepatic steatosis and incident cardiovascular disease and all-cause mortality	41
Letter to the Editor: Scavenger receptor a is a major homeostatic regulator that restrains drug-induced liver injury	41
Multicentered study of patient outcomes after declined for early liver transplantation in severe alcohol-associated hepatitis	41
Telehealth interventions in patients with chronic liver diseases: A systematic review	41
Letter to the Editor: More questions than answers—Response to the POP-NEXT project	41
Myofibroblast‐Specific Msi2 Knockout Inhibits HCC Progression in a Mouse Model	41
What is in a name? Toward culturally sensitive nomenclature for liver disease in the east and west	41
Reply: Machine learning models for NAFLD/NASH and cirrhosis diagnosis and staging: accuracy and routine variables are the success keys	41
Liver Disease and Coronavirus Disease 2019: From Pathogenesis to Clinical Care	40
Liver Sinusoidal Endothelial Cells Suppress Bone Morphogenetic Protein 2 Production in Response to TGFβ Pathway Activation	40
Cost-effectiveness of MRE versus VCTE in staging fibrosis for nonalcoholic fatty liver disease (NAFLD) patients with advanced fibrosis	40
Lean NAFLD is associated with adverse liver events and mortality: Moving beyond BMI	40
A multidisciplinary approach to the diagnosis and management of Wilson disease: Executive summary of the 2022 Practice Guidance on Wilson disease from the American Association for the Study of Liver D	40
An integrated analysis of fecal microbiome and metabolomic features distinguish non-cirrhotic NASH from healthy control populations	39
Predicting liver outcomes with biomarker monitoring in MASLD	39
Fructose‐1,6‐Bisphosphate Aldolase B Depletion Promotes Hepatocellular Carcinogenesis Through Activating Insulin Receptor Signaling and Lipogenesis	39
A genome-wide association study identified PTPN2 as a population-specific susceptibility gene locus for primary biliary cholangitis	39
Single-cell dissection of the multicellular ecosystem and molecular features underlying microvascular invasion in HCC	39
Performance of American Gastroenterological Association Clinical Care Pathway for the risk stratification of patients with nonalcoholic fatty liver disease in the US population	39
Inhibition of Secretin/Secretin Receptor Axis Ameliorates NAFLD Phenotypes	39
Prevalence of subclinical hypothyroidism and longitudinal thyroid-stimulating hormone changes in youth with metabolic dysfunction–associated steatotic liver disease: An observational study	38
Letter to the Editor: Survival benefit of transarterial chemoembolization combined with tyrosine kinase and immune checkpoint inhibitors as conversion therapy for unresectable hepatocellular carcinoma	38
Serum biomarkers correlated with liver stiffness assessed in a multicenter study of pediatric cholestatic liver disease	38
The macrophage STING-YAP axis controls hepatic steatosis by promoting the autophagic degradation of lipid droplets	38
Letter to the Editor: There may be a misunderstanding about the function of circular RNA as miRNA sponges	38
Intrahepatic cholangiocarcinoma PANoptosidy	38
Breakthrough SARS‐CoV‐2 infection outcomes in vaccinated patients with chronic liver disease and cirrhosis: A National COVID Cohort Collaborative study	38
Antiviral therapy substantially reduces HCC risk in patients with chronic hepatitis B infection in the indeterminate phase	38
Evaluating the risk-benefit ratio of immunotherapy according to liver-functional reserve in advanced HCC: the dark side of the moon	38
Effect of phospholipid curcumin Meriva on liver histology and kidney disease in nonalcoholic steatohepatitis: A randomized, double-blind, placebo-controlled trial	38
A global action agenda for turning the tide on fatty liver disease	37
Cordycepin Ameliorates Nonalcoholic Steatohepatitis by Activation of the AMP‐Activated Protein Kinase Signaling Pathway	37
The evolving role of liver sinusoidal endothelial cells in liver health and disease	37
The Use of Rifaximin in Patients With Cirrhosis	37
Corticosteroids for high‐grade immune checkpoint inhibitor–mediated hepatitis: Is less more?	37
Transcriptomics Identify Thrombospondin‐2 as a Biomarker for NASH and Advanced Liver Fibrosis	37